Heat-stable toxin type I (STa)-ovalbumin chemical conjugates are currently used as the only coating antigen in ELISA to titrate anti-STa antibodies for ETEC vaccine candidates. STa-ovalbumin chemical conjugation requires STa toxin purification, a process that can be carried out by only a couple of laboratories and often with a low yield. Alternative ELISA coating antigens are needed for anti-STa antibody titration for ETEC vaccine development. In the present study, we genetically fused STa toxin gene (three copies) to a modified chicken ovalbumin gene for genetic fusion 3ÂSTa-ovalbumin, and examined application of this fusion protein as an alternative coating antigen of anti-STa antibody titration ELISA. Data showed fusion protein 3ÂSTa-ovalbumin was effectively expressed and extracted, and anti-STa antibody titration ELISA using this recombinant protein (25 ng per well) or STa-ovalbumin chemical conjugates (10 ng/well) showed the same levels of sensitivity and specificity. Furthermore, mice immunized with this fusion protein developed anti-STa antibodies; induced antibodies showed in vitro neutralization activity against STa toxin. These results indicate that recombinant fusion protein 3ÂSTa-ovalbumin is an effective ELISA coating antigen for anti-STa antibody titration, enabling a reliable reagent supply to make standardization of STa antibody titration assay feasible and to accelerate ETEC vaccine development.
Enterotoxigenic Escherichia coli (ETEC) is a leading bacterial cause of diarrhea in humans and livestock animals. The virulence factors are ETEC bacterial adhesins and enterotoxins. Adhesins mediate ETEC bacterial attachment to host cell receptors and colonization in host small intestines. Enterotoxins including LT (heat-labile toxin) and ST (heat-stable toxin) disrupt fluid homeostasis in small intestinal epithelial cells, leading to fluid hypersecretion and watery diarrhea. Vaccines against ETEC attachment and enterotoxicity are considered the most effective and practical to prevent ETEC diarrhea (1-3). The major challenge in ETEC vaccine development is heterogeneity of virulence factors, as different ETEC strains express immunologically heterogeneous adhesins and enterotoxins. Inability to induce immunity to protect against STa used to be another major difficulty in ETEC vaccine development. STa is highly prevalent in ETEC strains causing diarrhea in young animals (4) and also children's diarrhea and travelers' diarrhea (5) . Indeed, STa-producing ETEC is the third leading cause of moderate-to-severe diarrhea in young children living in developing countries (6) . Therefore, an effective ETEC vaccine is urgently needed.
However, measuring anti-STa antibody responses induced by ETEC vaccine candidates remains problematic. STa-ovalbumin chemical conjugates are currently the only coating antigen used in ELISA to titrate anti-STa antibodies (7, 8) . Chemical conjugation requires purified STa toxin; but purifying the 18-or 19-amino-acid STa toxin is very challenging. There are only a couple of laboratories capable of purifying biologically active STa toxin, often at a yield of as low as 0.5-1 mg per liter of growth medium. Additionally, conjugating STa to ovalbumin is not effective. This leads to very limited supply of STa-ovalbumin conjugates, concerns of uniformity of the conjugation products, and inconsistency of assay results.
Alternative coating antigens are needed to effectively measure anti-STa antibodies for ETEC vaccine development. In the present study, we genetically fused humantype STa gene (hSTa; 19 amino acids) to a modified chicken ovalbumin gene for a STa-ovalbumin chimeric gene to express recombinant fusion protein, and investigated STa-ovalbumin fusion protein as an alternative coating antigen in ELISA to effectively titrate anti-STa antibody response.
MATERIALS AND METHODS

Construction of 3ÂSTa-ovalbumin chimeric gene
Three copies of human-origin ETEC STa toxin gene (estA) were genetically fused to a modified chicken ovalbumin gene. This ovalbumin gene was first modified with truncation of introns and then optimized for codon usage to be expressed in E. coli. Optimized ovalbumin gene was synthesized. Three copies of STa gene were fused at the N-terminus, C-terminus, and in the middle of the modified ovalbumin gene, using SOE PCR as described previously (7) . A GPVD linker was inserted between the STa gene and the 5 0 or the 3 0 end of the modified ovalbumin gene (Fig. 1a) .
Expression and detection of 3ÂSTa-ovalbumin fusion protein
The STa-ovalbumin chimeric gene was cloned into expression vector pET28a (Novagen, Madison, WI, USA) and expressed in E. coli BL21 (GE Healthcare, Piscataway, NJ, USA). Expression and purification of 3ÂSTa-ovalbumin fusion protein was examined in a standard SDS-PAGE as described previously (8) . Briefly, the fusion recombinant strain was cultured in 200 mL YT medium supplemented with kanamycin (30 mg/mL) at 37°C. Overnight-grown bacteria were induced with isopropyl-1-thio-b-D-galactoside (IPTG; 0.1 mM) for 4 hr after the culture OD reached approximately 0.5. Bacterial culture was centrifuged at 5000 Â g for 20 min, and bacteria pellets were suspended with 5 mL bacterial protein extraction reagent (B-PER; Pierce, Rockford, IL, USA) in phosphate buffer for total protein extraction (with a majority of proteins as inclusion bodies; in denatured buffer). Recombinant fusion protein was further extracted from total insoluble proteins and washed with PBS to a purity of >90%, refolded using a Novagen protein refolding kit according to the manufacturer's protocol (Novagen), and then dialyzed with PBS at 4°C overnight.
Purified 3ÂSTa-ovalbumin fusion protein was examined using 12% SDS-PAGE gel with Coomassie blue staining. Fusion protein was also characterized in a Western blot assay with rabbit anti-STa antiserum (1:3000; gift from Dr Ronald C Robertson at Kansas State University) as the primary antibody, and IRDye-labeled goat anti-rabbit immunoglobulin IgG (1:10 000; LI-COR, Lincoln, NE, USA) as the secondary antibody. Antibody recognized protein was detected with a 
LI-COR Odyssey premium infrared gel imaging system (LI-COR).
Dose optimization of fusion protein as the anti-STa ELISA coating antigen 3ÂSTa-ovalbumin fusion protein, 6.25, 12.5, 25, 50 or 100 ng per well, or STa-ovalbumin chemical conjugates at 10 ng per well, in 100 mL STa ELISA buffer, was used to coat Costar plates (Corning, Inc., Corning, NY, USA) in anti-STa antibody titration ELISA. After incubation at 37°C for 1 hr and then 4°C overnight, coated plates were washed with PBST (PBS with 0.05% Tween 20) and blocked with 10% non-fat milk-PBST (200 mL per well) at 37°C for 1 hr. After three washes with PBST, wells were incubated with two-fold serial dilutions of pig anti-STa serum samples of pig previously immunized with 3ÂSTaN12S-dmLT fusion protein (100 mL; at an initial dilution of 1:400) for 1 hr at 37°C. All samples were examined in triplicate. Wells were washed (three times with PBST) and incubated with HRP-conjugated goat anti-pig IgG (1:3000; 100 mL per well) for 1 hr at 37°C. The plates were washed again (three times with PBST) and incubated with TMB Microwell Peroxidase Substrate (2-C) (KPL, Gaithersburg, MD, USA) (100 mL per well) for 30 min at room temperature. OD was measured with a plate reader at a 650 nm wavelength.
Sensitivity and specificity of anti-STa antibody titration ELISA with 3ÂSTa-ovalbumin fusion protein as coating antigen
To measure assay sensitivity using the fusion protein coating antigen in STa antibody titration ELISA, 25 ng STa-ovalbumin fusion protein was coated in each well. Two-fold serial dilutions of pig anti-STa serum samples (dilutions from 1:400 to 1:204 800) were added to each well to titrate anti-STa IgG antibodies. To test specificity of the assay, a total of 85 positive or negative serum samples collected from mice, pigs and rabbits immunized with 3ÂSTaN12S-dmLT fusion protein were included in ELISA using STa-ovalbumin fusion protein as the coating antigen. Anti-STa antibodies from these mouse, pig or rabbit serum samples were verified in ELISA using 10 ng/well STa-ovalbumin chemical conjugates as coating antigen. OD 650 value of >0.3, after subtraction of the background readings, was set as the threshold of anti-STa positivity. All samples were examined in triplicate.
Mouse immunization with purified 3ÂSTa-ovalbumin fusion protein
To verify whether 3ÂSTa-ovalbumin fusion protein retains STa antigenic property and structure integrity, 
Mouse serum anti-STa antibody titration
Anti-STa IgG antibodies in serum of each mouse were titrated as described previously (7). Briefly, 96-well Costar plates (Corning Inc.) were coated with STaovalbumin chemical conjugates (10 ng per well) to titrate anti-STa IgG antibodies. All serum samples were examined in triplicate. HRP-conjugated goat anti-mouse IgG second antibodies (1:3300; Sigma, St Louis, MO, USA) and Microwell Peroxidase Substrate System (2-C) (KPL) were used to measure OD at the wavelength of 650 nm. Antibody titers were calculated as described above.
Anti-STa antibody neutralization assay
Mouse serum samples pooled from the control group and the immunized group were examined for in vitro antibody neutralization activities against STa using EIA cGMP kits (Enzo Life, Farmingdale, NY, USA). As described previously (7), 30 mL pooled serum sample of the immunization group or the control group was preincubated with 2 ng STa toxin (gift from Dr Robertson) for 30 min at room temperature, and then the mixture was added to T-84 cells. After incubation in a CO 2 cell incubator for 1 hr, the cGMP concentration in T-84 cells was measured with an EIA cGMP kit by following the manufacturer's protocol (Enzo Life). Two ng STa alone (without serum) were used as the positive control to show enterotoxicity for stimulation of cGMP in T-84 cells, and culture medium only was used to show a baseline of intracellular cGMP level in T-84 cells.
Statistical analysis
Data were analyzed using Student's t-test for independent samples. Differences were considered significant if P 0.05.
RESULTS
Fusion protein 3ÂSTa-ovalbumin was expressed and extracted DNA sequencing verified that the 3ÂSTa-ovalbumin chimeric gene carried three copies of the STa gene and the intron-truncated ovalbumin gene (Fig. 1a) . The first copy of the STa gene (without the stop codon) with a 'GPVD' linker was located at the 5 0 end of the modified ovalbumin gene, the second STa (without the stop codon) was between nucleotides coding the 191 and the 192 amino acid of ovalbumin peptide, and the third copy of STa gene (with the stop codon) with a 'GPVD' linker was at the 3 0 end of the ovalbumin gene. Expression of the fusion protein was verified in SDS-PAGE and Western blot. Coomassie blue staining SDS-PAGE showed a protein with molecular mass of approximately 40 KDa, the expected size of the STa-ovalbumin fusion protein, and at a purity of over 90% (Fig. 1b) . This 3ÂSTa-ovalbumin fusion protein was recognized by rabbit anti-STa antiserum (gift from Dr Robertson) in Western blot assay (Fig. 1c) . Fusion protein expression yield was measured at 40 mg per liter of bacterial growth medium.
ELISA with 3ÂSTa-ovalbumin fusion protein coating antigen effectively titrated anti-STa antibodies
Of ELISA using five coating antigen doses (6.25, 12.5, 25, 50 or 100 ng per well), 100 ng per well was able to detect the highest dilution of serum sample. However, the one coated with 25 ng STa-ovalbumin fusion protein per well showed equivalent detection of antiSTa IgG titers as the ELISA coated with 10 ng STaovalbumin conjugates per well, with a positive mouse serum sample (Fig. 2) .
ELISA with the 3ÂSTa-ovalbumin fusion protein was shown to be sensitive and specific for detecting anti-STa antibody response Anti-STa antibody titration ELISA using 3Â STa-ovalbumin fusion protein (25 ng/well) detected anti-STa antibody responses at a dilution of 1:51 200 from pig positive serum samples (Fig. 3) . Moreover, compared with detection in ELISA using STa-ovalbumin chemical conjugates as coating antigen, the overall detection accuracy for anti-STa antibodies in the ELISA using STa-ovalbumin fusion antigen was 100% (Table 1) . Fig. 2 . Coating antigen dose optimization in anti-STa antibody titration ELISA using the fusion protein, with 10 ng STaovalbumin conjugates as the reference. Each well of a microtiter plate was coated with 6.25, 12.5, 25, 50, or 100 ng 3ÂSTa-ovalbumin fusion protein, or 10 ng STa-ovalbumin chemical conjugate for ELISA, with pig anti-STa anti-serum (pig immunized with 3ÂSTaN12S-dmLT fusion protein) as the primary antibody, and HRP-conjugated goat-antipig IgG (1:3000) as the secondary antibodies. The antibody titer was calculated from the highest dilution of the serum sample that produced an ELISA optical density of >0.3 (above the background) and is presented in a log 10 scale.
ÃÃ Statistically significant difference when compared to anti-STa antibody titers detected from ELISA using 10 ng STa-ovalbumin chemical conjugates as the coating antigen (P < 0.001). 
Mice immunized with 3ÂSTa-ovalbumin fusion protein induced neutralizing anti-STa antibodies
Each mouse immunized with 3ÂSTa-ovalbumin fusion protein developed anti-STa antibody response (Fig. 4) . Anti-STa IgG antibody titers were detected at 2.33 AE 0.05 (log 10 ) from the immunized group. Serum of the control mice had no anti-STa antibodies detected. Serum of the mice immunized with 3ÂSTa-ovalbumin fusion protein showed antibody neutralization activity against STa toxin (Fig. 5) . The cGMP levels in the T-84 cells incubated with 2 ng STa and serum of the immunized mice were 13.76 AE 0.86 pmol/mL, which were significantly lower than the cGMP in cells incubated with only 2 ng STa (50.05 AE 1.23 pmol/mL; P < 0.01) or with STa toxin and the serum of the control mice (45.95 AE 1.77 pmol/mL; P < 0.01).
DISCUSSION
Effective ETEC vaccines need to induce antibodies against STa toxin, because STa is highly prevalent and virulent in ETEC strains associated with diarrhea (4, 5) . To measure antibody responses, the relatively inexpensive but rapid and reliable antibody titration ELISA are commonly used (11) . However, measuring anti-STa antibody responses induced by ETEC vaccine candidates has encountered challenge. Currently, only STa-ovalbumin chemical conjugates were used as the coating antigen in ELISA to measure anti-STa antibody responses (7, 8) . However, preparation of STa-ovalbumin chemical conjugates is complicated and often resulted in variable and low yield (9, 10) . Development of alternative coating antigens for anti-STa antibody ELISA is warranted. Data from the current study suggested that recombinant fusion protein 3ÂSTa-ovalbumin is an alternative coating antigen for ELISA to effectively measure anti-STa antibody response. Data from the current study indicated that 3ÂSTa-ovalbumin fusion protein (25 ng per well) was equivalent to STa-ovalbumin chemical conjugates (10 ng per well) in ELISA to detect anti-STa antibody response. We fused three copies of STa to the carrier protein to enhance detection of anti-STa antibody response. It was reported that STa toxoid fusions had anti-STa immunogenicity enhanced when additional copy or copies were genetically fused to a carrier protein (7) . The fusion protein carrying three copies of STa toxin may maintain similar copy numbers of STa as the STa-ovalbumin conjugate which was estimated to have 3-5 STa molecules conjugated to one ovalbumin molecule (communication with Dr Robertson). Results from the present study showed that ELISA using 25 ng recombinant fusion protein or 10 ng chemical conjugates (per well), provided nearly identical anti-STa antibody titers from the same pig serum samples. This may suggest that each STaovalbumin chemical conjugate likely possesses more than three copies of STa.
Compared to STa-ovalbumin chemical conjugation, preparation of STa-ovalbumin recombinant protein is reliable and less complicated. STa-ovalbumin conjugation requires purified STa toxin and the conjugation process can be less consistent. In contrast, the use of E. coli for protein expression is well documented for its advantages including low cost, easy procedure and high protein yields (12) . The E. coli expressed 3ÂSTa-ovalbumin recombinant fusion protein from this study was shown to be purified consistently at a yield of 40 mg per liter culture and with a purity of over 90%, and SDS-PAGE suggested a high uniformity of the extracted recombinant protein product. Although future studies are needed to better characterize the extracted fusion protein, a supply of 3ÂSTa-ovalbumin fusion protein with high yield and purity enables us to optimize and further standardize anti-STa antibody titration ELISA, leading toward acceleration of ETEC vaccine development.
Data from the present study showed that ELISA using 3ÂSTa-ovalbumin fusion protein was as specific and as sensitive as the ELISA using STa-ovalbumin conjugates. Serum samples used to assess ELISA sensitivity and specificity in this study were from mice, rabbits or pigs immunized with ETEC fusion antigens carrying STa or STa toxoids. Data showed that ELISA using STa-ovalbumin chemical conjugate coating antigen or the 3ÂSTa-ovalbumin fusion protein coating antigen had the same detection sensitivity and specificity. It must be pointed out that only serum samples from controlled immunization studies were used as the positive samples. Large sample size can surely better validate the sensitivity and specificity of this assay. Unfortunately, we were unable to include any other positive samples in this sensitivity assay and study. There are simply no natural anti-STa positive sera as a result of the poorly immunogenic STa which does not induce anti-STa antibody response in ETEC infection.
In addition, this 3ÂSTa-ovalbumin fusion protein showed anti-STa immunogenicity. Mice immunized with the fusion protein induced strong anti-STa antibody responses. Moreover, induced anti-STa antibodies exhibited neutralizing activities against STa toxin. This suggested that STa carried by the fusion protein had enhanced STa immunogenicity, and likely maintained STa antigenic structure. Certainly, future biochemical studies including protein stability and protein structure will further characterize this fusion protein.
In conclusion, the recombinant 3ÂSTa-ovalbumin fusion protein produced in a simple, fast and less expensive procedure was equally effective as the STaovalbumin chemical conjugates to measure anti-STa antibody response. Moreover, the fusion protein elicited specific anti-STa antibody responses, and the anti-STa antibodies neutralized STa toxin in vitro. These results indicated that this 3ÂSTa-ovalbumin fusion protein can be used as an alternative effective ELISA coating antigen for STa antibody titration.
